
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Avoiding Thrombocytopenia Through Differentiated Safety
Stefanie Fluckiger-Mangual says earlier CBP inhibitors were limited by thrombocytopenia, while TT125-802 showed no cases among 45 patients.
Play episode from 02:39
Transcript


